DK175348B1 - Orale zidovudinpræparater til kontrolleret frigivelse - Google Patents

Orale zidovudinpræparater til kontrolleret frigivelse Download PDF

Info

Publication number: DK175348B1
Authority: DK; Denmark
Prior art keywords: coating; zidovudine; pharmaceutical compositions; compositions according; pharmaceutical
Prior art date: 1987-03-27

Application number

DK198801643A

Other languages

Danish (da)

English (en)

Other versions

DK164388D0 (da

DK164388A (da

Inventor

Michael John Desmond Gamlen

Harry Phillip Jones

Jobert Judson Mackey

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-27

Filing date

1988-03-25

Publication date

2004-09-06

1988-03-25 Application filed by Wellcome Found filed Critical Wellcome Found

1988-03-25 Publication of DK164388D0 publication Critical patent/DK164388D0/da

1988-09-28 Publication of DK164388A publication Critical patent/DK164388A/da

2004-09-06 Application granted granted Critical

2004-09-06 Publication of DK175348B1 publication Critical patent/DK175348B1/da

Links

HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 title claims abstract description 17
229960002555 zidovudine Drugs 0.000 title claims abstract description 16
238000013270 controlled release Methods 0.000 title claims abstract description 10
238000002360 preparation method Methods 0.000 title description 5
238000000576 coating method Methods 0.000 claims abstract description 32
239000011248 coating agent Substances 0.000 claims abstract description 25
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
239000000203 mixture Substances 0.000 claims description 20
239000002245 particle Substances 0.000 claims description 18
239000002775 capsule Substances 0.000 claims description 13
239000000546 pharmaceutical excipient Substances 0.000 claims description 13
229920000642 polymer Polymers 0.000 claims description 10
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
229930195725 Mannitol Natural products 0.000 claims description 9
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
239000000594 mannitol Substances 0.000 claims description 9
235000010355 mannitol Nutrition 0.000 claims description 9
239000008108 microcrystalline cellulose Substances 0.000 claims description 9
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 6
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 5
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
239000001856 Ethyl cellulose Substances 0.000 claims description 3
125000005907 alkyl ester group Chemical group 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 3
229920001249 ethyl cellulose Polymers 0.000 claims description 3
235000019325 ethyl cellulose Nutrition 0.000 claims description 3
239000008240 homogeneous mixture Substances 0.000 claims description 2
229920001519 homopolymer Polymers 0.000 claims description 2
239000000178 monomer Substances 0.000 claims description 2
239000011148 porous material Substances 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
208000030507 AIDS Diseases 0.000 description 13
239000004480 active ingredient Substances 0.000 description 11
239000003814 drug Substances 0.000 description 10
229940079593 drug Drugs 0.000 description 9
238000001125 extrusion Methods 0.000 description 9
239000008213 purified water Substances 0.000 description 8
239000006185 dispersion Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000000463 material Substances 0.000 description 6
239000008188 pellet Substances 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 5
239000011230 binding agent Substances 0.000 description 5
238000000034 method Methods 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
206010038997 Retroviral infections Diseases 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
239000012729 immediate-release (IR) formulation Substances 0.000 description 4
229940069328 povidone Drugs 0.000 description 4
102220289725 rs778831047 Human genes 0.000 description 4
238000011282 treatment Methods 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
229920003134 Eudragit® polymer Polymers 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
206010001513 AIDS related complex Diseases 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
239000005995 Aluminium silicate Substances 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
235000012211 aluminium silicate Nutrition 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000004927 clay Substances 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000011049 filling Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
ZHNFLHYOFXQIOW-AHSOWCEXSA-N (s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid;dihydrate Chemical compound O.O.OS(O)(=O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-AHSOWCEXSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
229920003155 Eudragit® RL 100 Polymers 0.000 description 1
229920003159 Eudragit® RS 100 Polymers 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
241001122767 Theaceae Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
229960000892 attapulgite Drugs 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000012612 commercial material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229910052625 palygorskite Inorganic materials 0.000 description 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000009331 sowing Methods 0.000 description 1
230000001148 spastic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK198801643A 1987-03-27 1988-03-25 Orale zidovudinpræparater til kontrolleret frigivelse DK175348B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8707421		1987-03-27
GB878707421A GB8707421D0 (en)	1987-03-27	1987-03-27	Pharmaceutical formulations

Publications (3)

Publication Number	Publication Date
DK164388D0 DK164388D0 (da)	1988-03-25
DK164388A DK164388A (da)	1988-09-28
DK175348B1 true DK175348B1 (da)	2004-09-06

Family

ID=10614823

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198801643A DK175348B1 (da)	1987-03-27	1988-03-25	Orale zidovudinpræparater til kontrolleret frigivelse

Country Status (17)

Country	Link
US (1)	US4917900A (de)
EP (1)	EP0284407B1 (de)
JP (1)	JP2719344B2 (de)
KR (1)	KR960013434B1 (de)
AT (1)	ATE63818T1 (de)
AU (1)	AU607474B2 (de)
CA (1)	CA1308026C (de)
DE (1)	DE3862974D1 (de)
DK (1)	DK175348B1 (de)
ES (1)	ES2033426T3 (de)
GB (1)	GB8707421D0 (de)
GR (1)	GR3002030T3 (de)
IE (1)	IE60605B1 (de)
IL (1)	IL85870A (de)
NZ (1)	NZ224026A (de)
PT (1)	PT87081B (de)
ZA (1)	ZA882168B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5051361A (en) *	1988-10-19	1991-09-24	Sigma Chemical Company	AZT immunoassays, derivatives, conjugates and antibodies
US4938966A (en) *	1988-11-30	1990-07-03	Riker Laboratories, Inc.	Controlled release flecainide acetate formulation
GB8912420D0 (en)	1989-05-31	1989-07-19	Schram Cornelius J	Ultrasonic systems
EP0452862B1 (de) *	1990-04-18	1995-07-19	Asahi Kasei Kogyo Kabushiki Kaisha	Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung
US5102668A (en) *	1990-10-05	1992-04-07	Kingaform Technology, Inc.	Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
ES2085023T3 (es) *	1991-06-21	1996-05-16	Acic Canada Inc	Procedimientos para la produccion de zidovudina.
KR100221695B1 (ko) *	1991-08-12	1999-09-15	그린 마틴, 브라이언 쥐 테슬리	약학적 구상 제형
ATE186544T1 (de) *	1992-08-04	1999-11-15	James M Dunn	Pharmazeutische formulierungen mit kontrollierter freigabe von 3'-azido-3'-deoxythymidin und verfahren zur verwendung
FR2698560B1 (fr) *	1992-11-30	1995-02-03	Virbac Laboratoires	Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US6245351B1 (en)	1996-03-07	2001-06-12	Takeda Chemical Industries, Ltd.	Controlled-release composition
DE19945982A1 (de) *	1999-09-24	2001-03-29	Knoll Ag	Geschwindigkeitsbestimmte Partikel
AU2276801A (en)	1999-12-20	2001-07-03	Schering Corporation	Extended release oral dosage composition
WO2001045668A2 (en) *	1999-12-20	2001-06-28	Schering Corporation	Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
BR0109602A (pt) *	2000-03-30	2004-06-29	Bristol Myers Squibb Co	Glóbulos de liberação controlada contendo estavudina
EP1516907B1 (de) *	2002-06-24	2012-01-25	Adeka Corporation	Flammschutzmittel und sie enthaltende flammfeste harzzusammensetzung
JP2006508134A (ja) *	2002-11-08	2006-03-09	グラクソ　グループ　リミテッド	医薬組成物
MXPA06003479A (es) *	2003-10-01	2006-06-08	Lupin Ltd	Una composicion farmaceutica de liberacion prolongada y un proceso para su preparacion.
GB0403247D0 (en) *	2004-02-13	2004-03-17	Tillotts Pharma Ag	A pharmaceutical composition
EP1730516A1 (de) *	2004-03-30	2006-12-13	Pfizer Products Incorporated	Verfahren und vorrichtung zur bewertung pharmazeutischer zusammensetzungen
WO2008065502A1 (en) *	2006-11-29	2008-06-05	Pfizer Products Inc.	Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008125940A2 (en) *	2007-04-17	2008-10-23	Pfizer Products Inc.	Nanoparticles comprising non-crystalline drug
US8703204B2 (en) *	2007-05-03	2014-04-22	Bend Research, Inc.	Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135852A2 (en) *	2007-05-03	2008-11-13	Pfizer Products Inc.	Pharmaceutical compositions comprising nanoparticles and casein
US8309129B2 (en) *	2007-05-03	2012-11-13	Bend Research, Inc.	Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149230A2 (en)	2007-06-04	2008-12-11	Pfizer Products Inc.	Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2162120B1 (de) *	2007-06-04	2016-05-04	Bend Research, Inc	Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
US20100215747A1 (en) *	2007-07-13	2010-08-26	Corey Jay Bloom	Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
WO2009073216A1 (en) *	2007-12-06	2009-06-11	Bend Research, Inc.	Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
EP2231169B1 (de) *	2007-12-06	2016-05-04	Bend Research, Inc.	Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
US20140271893A1 (en) *	2013-03-15	2014-09-18	Mcneil-Ppc, Inc.	Coated phenylephrine particles and use thereof in pharmaceutical formulations
ITUA20161799A1 (it) *	2016-03-18	2017-09-18	Recordati Ind Chimica E Farmaceutica S P A	Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
CN106333957A (zh) *	2016-08-19	2017-01-18	丁静	齐多夫定用于制备自身免疫性神经炎治疗药物的应用
WO2019038430A1 (en) *	2017-08-25	2019-02-28	Eleonor Sprl	COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERIN ALKALOID AND METHOD FOR PRODUCING THE SAME

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE145365C (de) *
BE785702A (fr) *	1971-07-14	1972-10-16	Roehm Gmbh	Produits de revetement de formes medicamenteuses et leur utilisation
BE787973A (fr) *	1971-09-04	1973-02-26	Beecham Group Ltd	Comprimes pharmaceutiques a effet retard
ES438635A1 (es) *	1974-06-24	1977-02-16	Shinetsu Chemical Co	Procedimiento para el revestimiento de moldes solidos de do-sificacion.
EP0052075A1 (de) *	1980-11-12	1982-05-19	Ciba-Geigy Ag	Körnige Arzneimittel-Retardform
EP0052076B1 (de) *	1980-11-12	1985-05-29	Ciba-Geigy Ag	Schnellzerfallende Arzneimittel-Presslinge
DE3045135A1 (de) *	1980-11-29	1982-06-09	Sandoz-Patent-GmbH, 7850 Lörrach	Pharmazeutische kompositionen enthaltende bioabbaubare polymere
DE3126703A1 (de) *	1981-07-07	1983-01-27	Dr. Karl Thomae Gmbh, 7950 Biberach	Bromhexin-retardform und verfahren zu ihrer herstellung
ZA825384B (en) *	1981-07-31	1983-05-25	Tillott J B Ltd	Orally administrable pharmaceutical compositions
IT1168014B (it) *	1981-08-05	1987-05-20	Erba Farmitalia	Forme farmaceutiche a cessione protratta
DK150008C (da) *	1981-11-20	1987-05-25	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS59193831A (ja) *	1983-04-18	1984-11-02	Sankyo Co Ltd	腸溶性製剤の製造法
JPS59227817A (ja) *	1983-06-07	1984-12-21	Toyo Jozo Co Ltd	持続性経口用ブレデニン製剤
JPH075457B2 (ja) *	1983-08-16	1995-01-25	ザウエルカムフアウンデ−シヨンリミテツド	調節された方法による有効成分の放出を可能にする医薬組成物
CH658188A5 (de) *	1984-03-23	1986-10-31	Ciba Geigy Ag	Lagerstabile schnellzerfallende pharmazeutische presslinge.
US4724232A (en) *	1985-03-16	1988-02-09	Burroughs Wellcome Co.	Treatment of human viral infections
ATE113603T1 (de) *	1985-03-16	1994-11-15	Wellcome Found	Antivirale nukleoside.
IE73219B1 (en) *	1985-03-16	1997-05-07	Wellcome Found	Therapeutic nucleosides
GB8506869D0 (en) *	1985-03-16	1985-04-17	Wellcome Found	Antiviral compound
GB8519310D0 (en) *	1985-07-31	1985-09-04	Zyma Sa	Granular active substances
IT1227336B (it) *	1987-09-11	1991-04-08	Squibb & Sons Inc	Composizione farmaceutica contenente un carico elevato di medicamento e procedimento per la sua preparazione

1987
- 1987-03-27 GB GB878707421A patent/GB8707421D0/en active Pending
1988
- 1988-03-25 CA CA000562420A patent/CA1308026C/en not_active Expired - Lifetime
- 1988-03-25 IE IE89988A patent/IE60605B1/en not_active IP Right Cessation
- 1988-03-25 NZ NZ224026A patent/NZ224026A/xx unknown
- 1988-03-25 PT PT87081A patent/PT87081B/pt not_active IP Right Cessation
- 1988-03-25 ES ES198888302657T patent/ES2033426T3/es not_active Expired - Lifetime
- 1988-03-25 JP JP63071708A patent/JP2719344B2/ja not_active Expired - Lifetime
- 1988-03-25 EP EP88302657A patent/EP0284407B1/de not_active Expired - Lifetime
- 1988-03-25 AT AT88302657T patent/ATE63818T1/de not_active IP Right Cessation
- 1988-03-25 DK DK198801643A patent/DK175348B1/da not_active IP Right Cessation
- 1988-03-25 US US07/173,261 patent/US4917900A/en not_active Expired - Lifetime
- 1988-03-25 ZA ZA882168A patent/ZA882168B/xx unknown
- 1988-03-25 DE DE8888302657T patent/DE3862974D1/de not_active Expired - Lifetime
- 1988-03-25 IL IL85870A patent/IL85870A/xx not_active IP Right Cessation
- 1988-03-25 AU AU13756/88A patent/AU607474B2/en not_active Expired
- 1988-03-25 KR KR1019880003222A patent/KR960013434B1/ko not_active Expired - Lifetime
1991
- 1991-05-30 GR GR91400615T patent/GR3002030T3/el unknown

Also Published As

Publication number	Publication date
NZ224026A (en)	1991-03-26
EP0284407A2 (de)	1988-09-28
CA1308026C (en)	1992-09-29
AU607474B2 (en)	1991-03-07
DK164388D0 (da)	1988-03-25
DE3862974D1 (de)	1991-07-04
EP0284407B1 (de)	1991-05-29
US4917900A (en)	1990-04-17
PT87081A (pt)	1988-04-01
DK164388A (da)	1988-09-28
IE60605B1 (en)	1994-07-27
KR960013434B1 (ko)	1996-10-05
ZA882168B (en)	1989-11-29
IE880899L (en)	1988-09-27
GB8707421D0 (en)	1987-04-29
AU1375688A (en)	1988-09-29
PT87081B (pt)	1992-07-31
ATE63818T1 (de)	1991-06-15
JP2719344B2 (ja)	1998-02-25
JPS63255230A (ja)	1988-10-21
GR3002030T3 (en)	1992-12-30
ES2033426T3 (es)	1993-03-16
EP0284407A3 (en)	1988-12-14
IL85870A (en)	1992-02-16
KR880010759A (ko)	1988-10-24

Legal Events

Date	Code	Title	Description
1995-05-08	PBP	Patent lapsed
2008-04-14	PUP	Patent expired

Publication	Publication Date	Title
DK175348B1 (da)	2004-09-06	Orale zidovudinpræparater til kontrolleret frigivelse
CN100364501C (zh)	2008-01-30	托吡酯药物组合物
US7282221B2 (en)	2007-10-16	Antiviral product, use and formulation thereof
RU2136283C1 (ru)	1999-09-10	Препарат с контролируемым высвобождением лекарства и способ его получения, способ лечения
US5028664A (en)	1991-07-02	Drug-release controlling coating material for long acting formulations
US20030104056A1 (en)	2003-06-05	Delayed release anti-viral product, use and formulation thereof
AU5993600A (en)	2001-01-30	Method for making granules with masked taste and instant release of the active particle
KR20010074914A (ko)	2001-08-09	오메프라졸 제형
CN1270026A (zh)	2000-10-18	具有贮存稳定释放模式的控释曲马朵制剂和其制备方法
WO1989002738A1 (en)	1989-04-06	Sustained-release nifedipine formulation
AU2008365126A1 (en)	2011-06-30	Tamsulosin pellets for fixed dose combination
Hîrjău et al.	2011	Preparation and Characterization of Pellets Containing a Non-steroidal Antiinflamatory Drug, Coated with an Enteric Polymer
CS239844B1 (cs)	1986-01-16	LieCivý přípravek rdjssdiHjúKi mexiletín a sposob jeho přípravy